Pertussis in adolescents

Alexander K.C. Leung, William Lane M. Robson, H. Dele Davies

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pertussis is a highly communicable respiratory infection caused by Bordetella pertussis. In spite of the widespread availability of effective vaccines and high levels of vaccination coverage, a significant resurgence in pertussis has been observed during the past 2 decades. The increase in reported cases is due in large part to infection in adolescents and adults, and waning immunity plays an important role. Pertussis in adolescents and adults often goes unrecognized because a persistent, uncharacteristic cough might be the only clinical presentation. Pneumonia is the most frequent complication. Culture and polymerase chain reaction are helpful in establishing the diagnosis if a specimen can be obtained early in the course of the illness. Serology is useful when the diagnosis is not suspected until a later stage. Treatment with a macrolide antibiotic is recommended for affected individuals, as well as for all household and other close contacts. Universal immunization is necessary for disease control. Immunization should begin in infancy and should continue with booster doses through adulthood. Two adolescent and adult formulations of acellular pertussis vaccine are licensed in North America and Europe. Both are combined with an adult formulation of diphtheria and tetanus toxoids. In the US, Adacel® (Sanofi Pasteur, Toronto, Ontario, Canada) is licensed for use in individuals aged 11 to 64 y while Boostrix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed for use in individuals aged 10 to 18 y. These vaccines are safe, immunogenic, and well tolerated. Routine vaccination of adolescents and adults is required for optimal control of pertussis.

Original languageEnglish (US)
Pages (from-to)353-361
Number of pages9
JournalAdvances in Therapy
Volume24
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Whooping Cough
Immunization
Vaccination
Vaccines
Acellular Vaccines
Diphtheria Toxoid
Pertussis Vaccine
Tetanus Toxoid
Belgium
Macrolides
Ontario
Serology
North America
Cough
Canada
Immunity
Pneumonia
Anti-Bacterial Agents
Polymerase Chain Reaction
Infection

Keywords

  • Adolescent
  • Pertussis
  • Universal immunization

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pertussis in adolescents. / Leung, Alexander K.C.; Robson, William Lane M.; Davies, H. Dele.

In: Advances in Therapy, Vol. 24, No. 2, 01.03.2007, p. 353-361.

Research output: Contribution to journalArticle

Leung, AKC, Robson, WLM & Davies, HD 2007, 'Pertussis in adolescents', Advances in Therapy, vol. 24, no. 2, pp. 353-361. https://doi.org/10.1007/BF02849904
Leung, Alexander K.C. ; Robson, William Lane M. ; Davies, H. Dele. / Pertussis in adolescents. In: Advances in Therapy. 2007 ; Vol. 24, No. 2. pp. 353-361.
@article{adc4eb119ca648a69fe7297bd2968664,
title = "Pertussis in adolescents",
abstract = "Pertussis is a highly communicable respiratory infection caused by Bordetella pertussis. In spite of the widespread availability of effective vaccines and high levels of vaccination coverage, a significant resurgence in pertussis has been observed during the past 2 decades. The increase in reported cases is due in large part to infection in adolescents and adults, and waning immunity plays an important role. Pertussis in adolescents and adults often goes unrecognized because a persistent, uncharacteristic cough might be the only clinical presentation. Pneumonia is the most frequent complication. Culture and polymerase chain reaction are helpful in establishing the diagnosis if a specimen can be obtained early in the course of the illness. Serology is useful when the diagnosis is not suspected until a later stage. Treatment with a macrolide antibiotic is recommended for affected individuals, as well as for all household and other close contacts. Universal immunization is necessary for disease control. Immunization should begin in infancy and should continue with booster doses through adulthood. Two adolescent and adult formulations of acellular pertussis vaccine are licensed in North America and Europe. Both are combined with an adult formulation of diphtheria and tetanus toxoids. In the US, Adacel{\circledR} (Sanofi Pasteur, Toronto, Ontario, Canada) is licensed for use in individuals aged 11 to 64 y while Boostrix{\circledR} (GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed for use in individuals aged 10 to 18 y. These vaccines are safe, immunogenic, and well tolerated. Routine vaccination of adolescents and adults is required for optimal control of pertussis.",
keywords = "Adolescent, Pertussis, Universal immunization",
author = "Leung, {Alexander K.C.} and Robson, {William Lane M.} and Davies, {H. Dele}",
year = "2007",
month = "3",
day = "1",
doi = "10.1007/BF02849904",
language = "English (US)",
volume = "24",
pages = "353--361",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "2",

}

TY - JOUR

T1 - Pertussis in adolescents

AU - Leung, Alexander K.C.

AU - Robson, William Lane M.

AU - Davies, H. Dele

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Pertussis is a highly communicable respiratory infection caused by Bordetella pertussis. In spite of the widespread availability of effective vaccines and high levels of vaccination coverage, a significant resurgence in pertussis has been observed during the past 2 decades. The increase in reported cases is due in large part to infection in adolescents and adults, and waning immunity plays an important role. Pertussis in adolescents and adults often goes unrecognized because a persistent, uncharacteristic cough might be the only clinical presentation. Pneumonia is the most frequent complication. Culture and polymerase chain reaction are helpful in establishing the diagnosis if a specimen can be obtained early in the course of the illness. Serology is useful when the diagnosis is not suspected until a later stage. Treatment with a macrolide antibiotic is recommended for affected individuals, as well as for all household and other close contacts. Universal immunization is necessary for disease control. Immunization should begin in infancy and should continue with booster doses through adulthood. Two adolescent and adult formulations of acellular pertussis vaccine are licensed in North America and Europe. Both are combined with an adult formulation of diphtheria and tetanus toxoids. In the US, Adacel® (Sanofi Pasteur, Toronto, Ontario, Canada) is licensed for use in individuals aged 11 to 64 y while Boostrix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed for use in individuals aged 10 to 18 y. These vaccines are safe, immunogenic, and well tolerated. Routine vaccination of adolescents and adults is required for optimal control of pertussis.

AB - Pertussis is a highly communicable respiratory infection caused by Bordetella pertussis. In spite of the widespread availability of effective vaccines and high levels of vaccination coverage, a significant resurgence in pertussis has been observed during the past 2 decades. The increase in reported cases is due in large part to infection in adolescents and adults, and waning immunity plays an important role. Pertussis in adolescents and adults often goes unrecognized because a persistent, uncharacteristic cough might be the only clinical presentation. Pneumonia is the most frequent complication. Culture and polymerase chain reaction are helpful in establishing the diagnosis if a specimen can be obtained early in the course of the illness. Serology is useful when the diagnosis is not suspected until a later stage. Treatment with a macrolide antibiotic is recommended for affected individuals, as well as for all household and other close contacts. Universal immunization is necessary for disease control. Immunization should begin in infancy and should continue with booster doses through adulthood. Two adolescent and adult formulations of acellular pertussis vaccine are licensed in North America and Europe. Both are combined with an adult formulation of diphtheria and tetanus toxoids. In the US, Adacel® (Sanofi Pasteur, Toronto, Ontario, Canada) is licensed for use in individuals aged 11 to 64 y while Boostrix® (GlaxoSmithKline Biologicals, Rixensart, Belgium) is licensed for use in individuals aged 10 to 18 y. These vaccines are safe, immunogenic, and well tolerated. Routine vaccination of adolescents and adults is required for optimal control of pertussis.

KW - Adolescent

KW - Pertussis

KW - Universal immunization

UR - http://www.scopus.com/inward/record.url?scp=34250843159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250843159&partnerID=8YFLogxK

U2 - 10.1007/BF02849904

DO - 10.1007/BF02849904

M3 - Article

C2 - 17565926

AN - SCOPUS:34250843159

VL - 24

SP - 353

EP - 361

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 2

ER -